Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00729157 · ClinicalTrials.gov registry record · Phase 2
Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
A Phase 2 study of Recurrent Thyroid Gland Carcinoma and Stage III Thyroid Gland Follicular Carcinoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
- 1
- Study location
NCT00729157 is a Phase 2 study of Recurrent Thyroid Gland Carcinoma and Stage III Thyroid Gland Follicular Carcinoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 41 participants, roughly in line with the 42-participant average among 3 other Recurrent Thyroid Gland Carcinoma trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT00729157, a Phase 2 study of Recurrent Thyroid Gland Carcinoma and Stage III Thyroid Gland Follicular Carcinoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial is studying how well aflibercept works in treating patients with recurrent and/or metastatic thyroid cancer that has not responded to radioactive iodine therapy. Aflibercept may stop the growth of tumor cells by blocking blood flow to the tumor and by carrying tumor-killing substances directly to thyroid cancer cells.
Conditions Studied
Interventions
- PROCEDURE Positron Emission Tomography
- OTHER Laboratory Biomarker Analysis
- RADIATION Fludeoxyglucose F-18
- OTHER Pharmacological Study
- BIOLOGICAL Ziv-Aflibercept
Study Locations (1)
New York
- Memorial Sloan-Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2008-08 |
| Est. Completion | 2012-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00729157
The ClinicalTrials.gov registry entry for NCT00729157 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 42-participant average among 3 other Recurrent Thyroid Gland Carcinoma trials with a reported enrollment target. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Recurrent Thyroid Gland Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Positron Emission Tomography is the first listed.
NCT00729157 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00729157 about?
NCT00729157 is a clinical study titled "Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy". This phase II trial is studying how well aflibercept works in treating patients with recurrent and/or metastatic thyroid cancer that has not responded to radioactive iodine therapy. Aflibercept may stop the growth of tumor cells by blocking blood flow to the tumor and by carrying tumor-killing subst...
What is the current status of trial NCT00729157?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2008-08. Estimated completion is 2012-11.
What conditions does trial NCT00729157 study?
This clinical trial studies the following conditions: Recurrent Thyroid Gland Carcinoma, Stage III Thyroid Gland Follicular Carcinoma, Stage III Thyroid Gland Papillary Carcinoma, Stage IV Thyroid Gland Follicular Carcinoma, Stage IV Thyroid Gland Papillary Carcinoma.
What interventions are being tested in trial NCT00729157?
The interventions under investigation include: Positron Emission Tomography (PROCEDURE), Laboratory Biomarker Analysis (OTHER), Fludeoxyglucose F-18 (RADIATION), Pharmacological Study (OTHER), Ziv-Aflibercept (BIOLOGICAL).
Who is sponsoring clinical trial NCT00729157?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00729157 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Thyroid Gland Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery
COMPLETED · Phase 2
Explore more on PlainTrial
Recurrent Thyroid Gland Carcinoma
All registered trials for this condition
Stage III Thyroid Gland Follicular Carcinoma
All registered trials for this condition
New York
All trials with a study site in New York
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.